Compare BridgeBio Pharma Inc (BBIO) vs Super Micro Computer Inc (SMCI) Price & Performance

BridgeBio Pharma (BBIO) trades at $84.67, up 0.22% today, with a bullish technical signal and strong analyst consensus. Despite missing Q2 2026 EPS estimates with a loss of $0.78 per share, revenue beat expectations as Attruby sales surged 311% year-over-year. The company maintains a high gross margin of 94.44% but reports negative net income and cash flow from operations, reflecting its growth investment phase.

The outlook is optimistic due to multiple late-stage pipeline catalysts, including three potential product launches by mid-2027 and an FDA decision on encaleret by May 2027. Risks include sustained cash burn, high debt of $1.72 billion, and clinical trial execution. The consensus price target of $104.56 implies significant upside if commercial execution succeeds.

Super Micro Computer (SMCI) trades at $36.75, up 16.85% on strong Q4 2026 earnings, beating EPS estimates with $1.70 actual versus $0.92 expected. The stock shows bullish technical signals with moving averages supporting upward momentum, while RSI indicates potential overbought conditions. Revenue surged 93% year-over-year to $11.1 billion in Q4, though slightly below the $11.6 billion consensus, with robust FY2027 guidance of $65–72 billion revenue highlighting AI-driven demand.

Outlook remains positive due to AI infrastructure growth and earnings beats, but risks include supply chain delays and high valuation multiples. Analysts maintain a $40.40 consensus target with 36% buy ratings. Investors should weigh strong cash flow and margin expansion against competitive pressures and macroeconomic volatility.